Analysts Set Coherus Biosciences Inc (CHRS) Target Price at $30.75

Coherus Biosciences Inc (NASDAQ:CHRS) has been given a consensus recommendation of “Buy” by the seven analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $30.75.

A number of research firms recently weighed in on CHRS. ValuEngine upgraded Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Zacks Investment Research downgraded Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, December 4th. Finally, BidaskClub upgraded Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 10th.

Shares of Coherus Biosciences stock traded down $0.10 during trading on Friday, reaching $13.64. The company’s stock had a trading volume of 754,952 shares, compared to its average volume of 752,143. The company has a debt-to-equity ratio of 8.29, a current ratio of 2.54 and a quick ratio of 2.49. Coherus Biosciences has a 12-month low of $8.32 and a 12-month high of $20.66. The company has a market cap of $935.70 million, a PE ratio of -4.24 and a beta of 3.64.

In related news, CFO Jean-Frederic Viret sold 3,000 shares of Coherus Biosciences stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $14.92, for a total value of $44,760.00. Following the sale, the chief financial officer now directly owns 13,185 shares in the company, valued at $196,720.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 19.57% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc raised its holdings in Coherus Biosciences by 12.3% during the fourth quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 998 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in Coherus Biosciences by 16.5% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,095 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 3,122 shares during the last quarter. Boston Advisors LLC raised its holdings in Coherus Biosciences by 12.7% during the fourth quarter. Boston Advisors LLC now owns 33,060 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 3,725 shares during the last quarter. Hound Partners LLC raised its holdings in Coherus Biosciences by 0.3% during the fourth quarter. Hound Partners LLC now owns 2,016,827 shares of the biotechnology company’s stock worth $18,252,000 after purchasing an additional 6,551 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Coherus Biosciences by 4.1% during the fourth quarter. Bank of New York Mellon Corp now owns 222,542 shares of the biotechnology company’s stock worth $2,013,000 after purchasing an additional 8,766 shares during the last quarter. Hedge funds and other institutional investors own 94.79% of the company’s stock.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Read More: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.